The Lupus Nephritis drugs in development market research report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Lupus Nephritis. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Lupus Nephritis - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued products.

GlobalData tracks 70 drugs in development for Lupus Nephritis by 63 companies/universities/institutes. The top development phase for Lupus Nephritis is phase ii with 22 drugs in that stage. The Lupus Nephritis pipeline has 68 drugs in development by companies and two by universities/ institutes. Some of the companies in the Lupus Nephritis pipeline products market are: Novartis, Johnson & Johnson and Alexion Pharmaceuticals.

The key targets in the Lupus Nephritis pipeline products market include Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19), Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5), and Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104).

The key mechanisms of action in the Lupus Nephritis pipeline product include Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19 (B Lymphocyte Surface Antigen B4 or Differentiation Antigen CD19 or T Cell Surface Antigen Leu 12 or CD19) with nine drugs in Phase II. The Lupus Nephritis pipeline products include seven routes of administration with the top ROA being Intravenous and ten key molecule types in the Lupus Nephritis pipeline products market including Monoclonal Antibody, and Small Molecule.

Lupus Nephritis overview

Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body’s immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with SLE develop lupus nephritis, but it can significantly impact those who do. Symptoms of lupus nephritis can vary widely, ranging from mild to severe, and can include high blood pressure; swelling, particularly in the legs, feet, hands, or face; dark urine or blood in the urine; proteinuria (excessive protein in the urine); reduced urine output; fatigue; and general discomfort.

For a complete picture of Lupus Nephritis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.